

1 **Blood biomarkers-defined subgroups show heterogeneity in post-acute**  
2 **COVID-19 syndrome: a rationale for precision medicine.**

3 **Benjamin Charvet<sup>1</sup>, Alexandre Lucas<sup>2</sup>, Justine Pierquin<sup>1</sup>, Joanna Brunel<sup>1</sup>, Steven Fried<sup>3</sup>,**  
4 **Corinne Bernis<sup>3</sup>, Zachary S. Orban<sup>3</sup>, Millenia Jimenez<sup>3</sup>, Barbara A. Hanson<sup>3</sup>, Lavanya**  
5 **Visvabharathy<sup>3</sup>, Igor J. Koralnik<sup>3</sup>, Hervé Perron<sup>1\*</sup>, PhD.**

6 <sup>1</sup>Geneuro-Innovation, Bioparc Laennec, 69008, Lyon, France.

7 <sup>2</sup> We-Met platform, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), plateau We-  
8 Met, Inserm UMR1297 and Université Paul Sabatier, Toulouse, France

9 <sup>3</sup> Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago,  
10 IL, USA

11 \* **Correspondence:** [hperron@geneuro.com](mailto:hperron@geneuro.com); Hervé Perron, Geneuro-Innovation, Bioparc Laënnec,  
12 60A Avenue Rockefeller, 69008, Lyon, France. tel : +33 437 902 997

13 **Keywords:** long COVID-19, post-COVID-19, PASC, SARS-CoV-2, Immunoglobulin isotype,  
14 HERV-W, TLR4, cytokine, neurofilament, cognitive symptoms, brain fog.

15 Word count: 2741.

16

17 **Abstract**

18 Acute COVID-19 can cause a post-infectious syndrome in a significant percentage of patients, with  
19 multifacted and long lasting symptoms. We hypothesized that this Post-Acute COVID syndrome  
20 (PASC) could result from various underlying causes, which may compromise the demonstration of  
21 efficacy for treatments evaluated on cohorts of heterogeneous patients.

22 To assess the feasibility of stratifying or characterizing subgroups of post-COVID-19 patients  
23 consistent with different indications in a precision medicine perspective, we tested serum biomarkers  
24 in a pilot cross-sectional study of patients with neuro-cognitive symptoms from the Northwestern  
25 University post-COVID-19 clinic (Chicago,USA). Patient health status was evaluated with the use of  
26 standardized PROMIS questionnaires and underwent validated cognitive tests with the NIH Toolbox.  
27 Serum biomarkers were chosen as proteins known to be involved in the pathogenic features of a  
28 neuro-inflammatory disease, i.e., multiple sclerosis, with a final selection of the most discriminant  
29 ones. A multi-isotypes serology against SARS-CoV-2 spike and nucleocapsid antigens was  
30 performed to allow detailed analyses of the humoral immune status.

31 Despite the limited numbers of this feasibility study, results showed that clinical data could not  
32 differentiate PASC patients with persisting neuro-cognitive impairment, while three major PASC  
33 subgroups were identified with serum biomarkers according to the presence or absence of the HERV-  
34 W ENV soluble protein combined with neurofilaments light chains and, to a lesser extent, with  
35 elevated levels of IL-6. SARS-CoV-2 serological results in PASC compared to healthy controls also  
36 revealed a significant increase of anti-Spike and/or Nucleocapsid IgM, IgA and, unexpectedly, IgE.  
37 For IgG, a significant difference was observed with Nucleocapsid only since anti-Spike IgG titers  
38 were normally elevated in vaccinated controls. This multi-Ig isotypes serology may provide  
39 additional information on the infectious and immunological status of individual patients and should  
40 be considered in face of a potential viral persistence in some individuals.

41 Altogether the results show the feasibility of using serum biomarkers to discriminate relevant  
42 subgroups or individual patients for precision medicine indications in post-COVID syndromes. This  
43 pilot study paves the way to further exploring biological assays for the definition of subtypes of  
44 PASC, also called long COVID, useful for the choice of relevant therapeutic strategies.

45

## 46 **1 Introduction**

47 The COVID-19 pandemic is now known to generate a post-viral syndrome with multifaceted and  
48 long-lasting symptoms, variably named “Long COVID”, “Post-COVID” or “Post-Acute sequelae of  
49 COVID-19 (PASC). Though the last denomination may suggest lingering post-infectious symptoms,  
50 e.g., ischemic tissue lesions following thrombotic events<sup>1</sup>, many symptoms appear to result from  
51 ongoing pathogenic processes with possible onset of chronicity<sup>2,3</sup>.

52 In June 2022, the center for disease control (CDC) of the USA published that “more than 40% of  
53 adults in the United States reported having COVID-19 in the past, and nearly one in five of those  
54 (19%) are currently still having symptoms of long COVID”<sup>4</sup>. In September 2022, the World Health  
55 Organization (WHO) published that “at least 17 million people in the WHO European Region  
56 experienced long COVID in the first two years of the pandemic; millions may have to live with it for  
57 years to come”<sup>5</sup>. The data points to a secondary pandemic caused by COVID-19, in the form of a  
58 post-COVID syndrome of unknown duration and evolution with overlapping symptoms that may  
59 result from various pathogenic factors and pathways<sup>6</sup>. In particular, persisting neurological and  
60 cognitive symptoms appear common and affect the quality of life on the long term<sup>7,8</sup>.

61 Diagnosing and managing such a complex syndrome is a challenge that requires understanding how  
62 to identify potentially differing mechanisms underlying the overlapping symptoms observed in these  
63 patients<sup>9</sup>. There is a need to identify markers which will differentiate between heterogeneous long-  
64 COVID subgroups and guide precision medicine where possible. For this purpose, we have selected  
65 biomarkers from factors already known to be involved in COVID-19 and also suspected to contribute  
66 to certain aspects of long COVID or PACS. We also focused on assays suitable for routine laboratory  
67 analyses on serum samples, which can be easily obtained from patients.

68 In the present pilot study on patients from a post-COVID clinic presenting with persistent symptoms  
69 such as abnormal fatigue, sleep disorders and dominant neuro-cognitive symptoms, we have thus  
70 studied (i) immunoglobulin isotypes of the humoral response against SARS-CoV-2 spike and  
71 nucleocapsid antigens, (ii) the presence of an endogenous retroviral protein, HERV-W ENV, shown  
72 to be pathogenic for the immune and nervous systems<sup>10-12</sup>, with virus-induced expression<sup>13-15</sup> and  
73 recently shown to predict disease severity when detected on lymphocytes from COVID-19 patients  
74<sup>16</sup>, (iii) the levels of major cytokines involved in COVID-19 inflammatory responses<sup>17</sup> and, because  
75 of neuro-cognitive symptoms, (iv) the levels of neurofilament light chain (NfL) known to be accurate  
76 biomarkers of neuronal impairment even when quantified in the peripheral blood<sup>18</sup>.

77

## 78 2 Methods

### 79 *Participants and clinical assessment*

80 This cross-sectional study was approved by the Northwestern University Institutional Review Board  
81 (STU00215866). Blood collection from patients and sample processing followed standard operating  
82 procedures with the appropriate approval of the Ethics and Scientific Committees (num.  
83 20210604/04/02). Written informed consent was obtained from all study participants. Importation of  
84 the human samples received the authorization IE-2022-2309 from the French ministry. Clinical and  
85 demographic data from PASC patients are presented in **Table 1**. PASC patient health status was  
86 evaluated with the use of standardized PROMIS questionnaires and underwent validated cognitive  
87 tests with the NIH Toolbox<sup>8,19,20</sup>.

### 88 *Immunoassays*

89 The detection of SARS-CoV-2 immunoglobulin isotypes (IgG, IgM, IgA and IgE) were performed  
90 on serum by Simple Western technology (ProteinSimple/BioTechne, CA, USA) with manufacturer's  
91 reagents according to their manual. HIS-tagged recombinant proteins of SARS-CoV-2 ((S)Spike, S1  
92 Subunit, S2 Subunit, S1 RBD and Nucleocapsid) were used to detect antibody responses to SARS-  
93 CoV-2. The area under the curve (AUC) for the electrophoregram peak corresponding to the  
94 immunodetection of each protein at the expected size was measured using Compass Software.

95 For the detection of HERV-W ENV antigen in serum analyses were also performed with simple  
96 western-Jess, according to the conditions provided in the patent "Method for the detection of the  
97 soluble hydrophilic oligomeric form of HERV-W envelope protein", published under ref.  
98 WO2019201908, with previously described sample treatment (32). The specific signal was expressed  
99 as the signal to noise (S/N) ratio, where the noise represents the mean+2SD of the background  
100 signals yielded by a panel of sera from healthy blood donors (EFS, Lyon-France). PASC samples  
101 were stored in freezers at -80°C for less than 6 months. All samples were kept frozen after their initial  
102 freezing until use (no freeze/thaw cycle before the immunoassay).

103 Serum levels of NfL (# SPCKB-PS-002448) and IL-6 (# SPCKC-PS-006520) were quantified with  
104 the fully automated immunoassay platform, Ella (ProteinSimple/Bio-technie, CA, USA). The lower  
105 limits of quantification (LLOQ) were provided by the supplier as a threshold for normal baselines 3  
106 pg/mL for IL-6. Age-standardized Z-scores were calculated for NfLs{Harp, 2022 #18599}. Serum  
107 samples were run in triplicate and results in pg/mL were calculated by the instrument software  
108 (SimplePlex Explorer, ProteinSimple/Bio-technie, USA).

### 109 *RT-qPCR*

110 Total RNA was obtained from PAXgene tubes used to collect whole blood samples and stored at -  
111 20°C. RNA extraction used NucleoSpin RNA Mini Kit (Macherey Nagel, 740955) according to the  
112 manufacturer's protocol. 200 ng of DNase-treated RNA was reverse-transcribed into cDNA using  
113 iScript cDNA Synthesis Kit (Bio-Rad, 1708891) according to the manufacturer's protocol. A control  
114 with no-RT was used to confirm the absence of contaminating DNA. 5 ng of initial RNA in RT  
115 reaction was used in RT-qPCR for HERV-W *ENV*, HERV-W *POL*, HERV-K *ENV*, SARS-CoV-2 N  
116 genes. Primer sequences (5' to 3'): HERV-K ENV Forward CTGAGGCAATTGCAGGAGTT, Reverse  
117 GCTGTCTCTTCGGAGCTGTT; HERV-W ENV Forward GTATGTCTGATGGGGGTGGAG,  
118 Reverse CTAGTCCTTTGTAGGGGCTAGAG; HERV-W POL Forward CCTGTACGTCCTGACTCTC,  
119 Reverse CTTGGGCTAATGCCTGGCC; SARS-CoV-2 N Forward AAACATCCCCACCAACAG,

120 Reverse CACTGCTCATGGATTGTT; B2M Forward TTA<sub>2</sub>CTCACGTCATTCAGCAG, Reverse  
121 GATGGATGAAACCCAGACAC. Assays used StepOnePlus instrument (Applied Biosystems) with  
122 Platinum SYBR Green (Invitrogen, 11744-500). Housekeeping gene beta-2 microglobulin (*B2M*)  
123 normalized the results. A melting curve analysis confirmed the specificity of amplification and the  
124 lack of non-specific products. Quantification used the threshold cycle (Ct) comparative method: the  
125 relative expression was calculated as follow:  $2^{-[DCt(\text{sample}) - DCt(\text{calibrator})]}$ , where  $DCt(\text{sample}) =$   
126  $[Ct(\text{target gene}) - Ct(\text{housekeeping gene})]$  and the  $DCt(\text{calibrator})$  was the mean of  $DCt$  of healthy  
127 controls.

## 128 *Statistics*

129 Statistical analyses were performed using Prism (version 9.0; GraphPad Software, La Jolla,  
130 California). Continuous data are expressed as means  $\pm$  SD, as indicated. Normal data distribution  
131 was assessed using the Shapiro-Wilk or D'Agostino & Pearson's test, assuming p-values  $\leq$  0.05.  
132 Statistical differences were determined using Student's test (two tailed) for compared groups with  
133 normal distributions, with Welch's correction when SDs of samples were significantly different (F  
134 test  $p < 0.01$ ) - Mann-Whitney U test (two tailed) was used for compared groups without normal  
135 distribution and Wilcoxon signed rank test (two tailed) was used for comparison when a group only  
136 or mostly comprised null or very low values for a given threshold. Chi-square (two tailed) test was  
137 used for comparison of numbers in categories, replaced by Fischer's exact test when one category  
138 had zero count. Correlation analyses were performed with Spearman test (two tailed). Statistical  
139 significance was set at  $p < 0.05$ .

140

### 141 3 Results

142 A total of 41 subjects (Table 1) were evaluated in this study. Controls (Ctrl) were caregivers or  
143 volunteers from hospital (n=10) and PASC patients previously diagnosed with acute COVID-19 and  
144 presenting with neuro-cognitive symptoms, (Neuro-PASC; n=31). These included 6 post-  
145 hospitalization Neuro-PASC (PNP) and 25 non-hospitalized Neuro-PASC (NNP) patients seen at  
146 Northwestern Medicine Neuro-COVID-19 clinic.

#### 147 *HERV-W ENV detection*

148 Following reports of HERV-W envelope RNA and protein in acute COVID-19 patients correlating  
149 with disease severity and markers of T-cell exhaustion<sup>16</sup>, this study analyzed HERV-W ENV RNA  
150 from whole blood and levels of soluble envelope protein (W-ENV) in serum from PASC compared  
151 to Ctrl. As shown in Figure 1 A-D, about one-half (11/23 with QC-passed RNA) of PASC  
152 individuals had elevated RNA levels and about one-third (10/31) had detectable W-ENV protein in  
153 serum, which was significantly different from Ctrl for both analyses (Wilcoxon Signed Rank test:  
154 Ctrl W=1.00, PASC W=177.00, N=7+23, p=0.0055 for whole blood RNA, and Ctrl W=10.00, PASC  
155 W=265.00, N=10+31, p=0.0020 for serum protein). RT-qPCR also detects non-coding RNA and it is  
156 known that HERV RNA could play physiological roles as regulatory non-coding long or small RNA  
157<sup>21,22</sup>. Nevertheless, the presence of circulating W-ENV protein, a potent TLR4 agonist, cannot be  
158 neutral<sup>12,23-26</sup>.

159 In Figure 1C PASC patients were stratified based on hospitalization status during acute SARS-CoV-2  
160 infection. Positive cases for W-ENV protein represented about one fourth in the NNP subgroup  
161 (24%, 6/25), but a majority in the PNP subgroup (67%, 4/6). The difference of W-ENV signal to  
162 noise values (S/N) between NNP and controls was significant (Wilcoxon Signed Rank test: Ctrl  
163 W=1.00, PASC W=21.00, N=10+25, p=0.0313) but, probably due to the low numbers, not between  
164 PNP and Ctrl. Interestingly, W-ENV positive (W-ENV+) PASC patients tended to be further from  
165 the date of infection (Fig. 1D). A significant difference in the time from onset of acute COVID-19  
166 between W-ENV+ and W-ENV- patients was confirmed (Unpaired t-test with Welch's correction:  
167 t=2,346, df=17,61, N=21+10, p=0.0309). Some of these cases had suffered from post-COVID  
168 symptoms for two years after the acute infection, which corresponded to the beginning of the  
169 pandemic.

170

#### 171 *SARS-CoV-2 -specific antibody responses*

172 To study the humoral immune response to SARS-CoV-2 infection in PASC patients, we measured  
173 the levels of all immunoglobulins (IgG, IgM, IgA and IgE) versus the control group (including  
174 vaccinated individuals) against SARS-CoV-2 nucleocapsid (N) and spike (S) antigens.

175 Anti-N IgG were detected in a subgroup of PASC patients but not in controls (Wilcoxon Signed  
176 Rank test: Ctrl W=0.00, PASC W=444.0, N=10+31, p<0.0001; Fig. 1E), whereas no difference with  
177 Ctrl was observed for the anti-S IgG (Fig. 1F), which mostly indicated that Ctrl had been vaccinated  
178 with this antigen. Comparing W-ENV positive and negative PASC patients showed that anti-N IgG  
179 antibodies were detected in both subgroups, each one remaining significantly different from Ctrl  
180 (Wilcoxon Signed Rank test: Ctrl W=0.00, PASC/W-ENV- W=193.0, N=10+21, p=0.0003; Ctrl  
181 W=0.00, PASC/W-ENV+ W=53.0, N=10+10, p=0.0039; Fig. 1G), but no difference was seen  
182 between PASC subgroups and Ctrl for anti-spike IgG (Fig. 1H).

183 As shown in Figure 2, IgM against both S and N proteins were only observed in a subgroup of PASC  
184 patients with a wide range of titers. But, despite a few IgM positive PASC cases, a significant  
185 difference was seen versus controls for anti-N IgM (Wilcoxon Signed Rank test: Ctrl W=1600,  
186 PASC W=476.0, N=10+31 p=0.0480; Fig. 2 A) and, with high significance, for anti-S IgM  
187 (Wilcoxon Signed Rank test: Ctrl W=-6.00, PASC W=183.0, N=10+29, p<0.0001; Fig. 2 B). Of  
188 note, two sera with non interpretable technical profiles were omitted.. IgA antibodies levels were  
189 shown to be significantly elevated in PASC versus Ctrl for both N and S antigens, but anti-N IgA  
190 better discriminated PASC versus Ctrl (Wilcoxon Signed Rank test: anti-N IgA, Ctrl W=16.00,  
191 PASC W=476.0, N=10+31 p<0.0001; anti-S IgA, Ctrl W=-2.00, PASC W=273.0, N=10+31  
192 p=0.0063; Fig. 2 C-D). Surprisingly, a subgroup of PASC patients had elevated IgE  
193 immunoglobulins against both N and S antigens (Wilcoxon Signed Rank test: anti-N IgE, Ctrl  
194 W=5.00, PASC W=336.0, N=10+31 p=0.0006; anti-S IgE, Ctrl W=14.00, PASC W=456.0, N=10+31  
195 p<0.0001 ), with a large range of positivity versus all negative controls (Fig. 2 E-F).

### 196 ***IL-6 quantification***

197 IL-6 was suggested to play a role in acute COVID-19 severity. In PASC, only a subgroup had  
198 elevated IL-6 (about 35%, 11/31) but, whereas most values were below the normal threshold  
199 (3pg/ml) in NNP, nearly all PNP (5/6) had elevated IL-6 levels in the serum with a significant  
200 difference from Ctrl (Mann Whitney test: U=3, N=10+6, p=0.0017; Fig. 3A). When W-ENV positive  
201 and negative PASC subgroups were compared, the W-ENV+ patients showed significantly higher IL-  
202 6 levels (Mann Whitney test: U=31, N=21+10, p=0.0011; Fig. 3B), consistently with the significant  
203 correlation found between PASC serum levels of HERV-W ENV and IL-6 (Spearman correlation  
204 test: r=0.5877, 95% CI 0.2847 to 0.7840, pairs N=31, p=0.0005; Fig. 3C). In figure 3D, PASC were  
205 stratified according to both anti-N SARS-CoV-2 IgG and W-ENV serum levels. All samples from the  
206 W-ENV+ subgroup had elevated IL-6 levels, when compared to all other W-ENV negative sera with  
207 or without anti-N IgG (Mann Whitney test: W-ENV+/IgG N+ Vs W-ENV-/IgG N-, U=7, N=8+9,  
208 p=0.0035; W-ENV+/IgG N+ Vs W-ENV-/IgG N+, U=10, N=8+13, p=0.0013; Fig. 3D).

### 209 ***Neuronal impairment biomarker: Neurofilament Light chain (NfL)***

210 We measured the levels of serum NfL in PASC with cognitive impairment, since shown to be an  
211 accurate peripheral biomarker of neuronal degeneration or injury within the central nervous system<sup>27</sup>  
212 (Figure 3E-G). Results were normalized with Z-score according to the age of the patients or control  
213 individuals, as already defined<sup>28</sup>.

214 No significant difference was found between the distributions of NfL serum levels in PNP versus  
215 NNP, nor Vs Ctrl (Fig. 3 E). Nonetheless, when stratified with W-ENV, all (100%, 10/10) W-ENV+  
216 patients had elevated levels of serum NfL while only 62% (13 out of 21) of W-ENV-negative sera  
217 had a NFL Z-scores above 0 (Fisher exact test = 0.0317 p<0.05,  $\alpha=1$ , N=31; Fig. 3 F). Moreover, Z-  
218 scores were all above zero in the subgroup with both W-ENV and anti-N IgG positivity which was  
219 significantly different from the anti-N IgG+ and W-ENV- subgroup (Unpaired t test with Welch's  
220 correction: t=2,688, df=17,61, N=22, p= 0,0152; Fig. 3G),.

### 221 ***Biomarker-defined subgroups***

222 Figure 3H represents clusters of all PASC patients studied for the above-mentioned serum  
223 biomarkers. Within the W-ENV+ subgroup the majority (7/10) of PASC were positive altogether for  
224 NfL, IL-6 and IgG anti N-SARS-CoV-2 but only one (1/21) in the W-ENV negative subgroup (Chi-  
225 square statistic=17.890, p=0.00002,  $\alpha=1$ , N=31 tested on all parameters). All W-ENV+ Neuro-PASC  
226 had positive serum levels of NfL (10/10). Moreover, within the W-ENV + subgroup, the NfL+  
227 cluster included all IL-6+ or Ig anti-N+ sera and therefore coincided with W-ENV positivity in  
228 Neuro-PASC patients, i.e., defined the same subgroup when combined with W-ENV positivity.

229 Matching with acute COVID effective hospitalization also, all HERV-W ENV+ patients from the  
230 PNP subgroup were positive for the three other biomarkers (NfL, IL-6 and IgG anti-N; data not  
231 shown).

232 Within the W-ENV- subgroup, a single case was positive for NfL, IL-6 and IgG anti-N altogether. As  
233 found to be the core parameters in the W-ENV+ subgroup, this may question the sensitivity of the  
234 present test for HERV-W ENV soluble antigen detection in serum. The patterns for single or double  
235 positivity appeared to be variable while only NfLs positive levels were dominant, thereby suggesting  
236 relationship with the neuro-cognitive impairment in this cohort. However, a cluster was clearly  
237 identified to be negative for all these biomarkers, beyond negativity for W-ENV as well. This “all  
238 negative” cluster is consistent with very different pathogenic factors involved in their post-COVID  
239 symptomatology.

240 Of note, though all W-ENV+ patients had positive Z-scores for NfL, taken alone this biomarker  
241 revealed dominant in all Neuro-PASC cases, W-ENV+ and W-ENV- (Figure 3F). Negative Z-scores  
242 were found in few cases positive for IL-6 only or for IgG anti-N only but, most interestingly, within  
243 the isolated cluster negative for all tested biomarkers (figure 3H).

244 SARS-CoV-2 serology showed significant differences with controls for anti-N IgG (Figure 1E) and  
245 for anti-N and/or anti-S IgM, IgA or IgE (Figures 2A-F). But, even in combination with other  
246 biomarkers, it did not provide a clear-cut stratification when considered without the other studied  
247 biomarkers.

248 Therefore, Neuro-PASC subgroups could be defined as (i) W-ENV+ and NfL+, (ii) W-ENV- and  
249 (NfL+ or IL-6+ or IgG anti-N+) and (iii) negative for all the tested parameters. In addition, possible  
250 indication may be also provided on SARS-CoV-2 persistence by IgM, on the route of infection in  
251 extrapulmonary cases<sup>29</sup> or on the site of persistence by IgA and, particularly, on potentially  
252 associated immunoallergic symptoms by IgE.

253 Finally, using data from the PROMIS scale<sup>30</sup> and other clinical data showed no significant difference  
254 in the distribution of results between the subgroups consistently defined by the different biomarkers  
255 as exemplified with HERV-W ENV and anti-N-SARS-CoV-2 IgG in Figure 4.

256

## 257 **Conclusion**

258 The present results, despite the limited number of patients, consistently identified three major Neuro-  
259 PASC subgroups with significant differences stratified according to the presence or absence of the  
260 HERV-W ENV protein combined with positive Z-score for NfLs in serum. SARS-CoV-2 serology  
261 with all Ig isotypes should also provide useful indications on the infectious status, with possible viral  
262 persistence or a possible immunoallergic specific phenotype linked to elevated anti-spike or  
263 Nucleocapsid IgE. Since clinical data could not differentiate consistent subgroups of patients, unlike  
264 biological parameters, the biomarker-defined subgroups or clusters may be considered for differing  
265 therapeutic indications in post-COVID treatment. This should be a prerequisite for clinical trials to  
266 avoid mixing patients with and without the pathogenic target of a given drug, which may generate  
267 non-significant results versus placebo, despite possibly responding cases. Thus, the presented  
268 biomarker and serology-based stratification should pave the way to precision medicine in post-acute  
269 COVID sequelae or syndromes. Based on the present proof of concept and on that of other studies , a  
270 diagnostic-based therapy with an anti-HERV-W ENV neutralizing antibody (Temelimab) is being  
271 evaluated in a clinical trial with PASC patients positive for the HERV-W ENV protein in serum  
272 (ClinicalTrials.gov Identifier: NCT05497089).

## 273 **Figure Legends**

274

275 **Figure 1. HERV-W ENV and Anti-Nucleocapsid IgG antibody are significantly detected in PASC.** A, HERV-W  
276 ENV mRNA detection in PBMCs based on change fold of  $2^{-\Delta\Delta CT}$  compared to the mean of control groups; blue dots:  
277 controls group; red dots: PASC group. Here, a lower number of samples was analyzed, since 8 PASC and 3 controls  
278 yielded too low RNA concentration or did not pass QC (RIN<8). B, HERV-W ENV soluble oligomeric protein detection  
279 in serum of patients, results are expressed on total signal normalized with the mean of background noise measured on  
280 control cohort; blue dots : controls group; red dots : PASC group. C, post-hospitalized subgroup (PNP) is extracted from  
281 the PASC group and compared to PASC subgroup not hospitalized during acute COVID-19 (NNP); blue dots: controls  
282 group; red dots: NNP subgroup; dark red dots: PNP sub group. D, Comparison of the time from onset between HERV-W  
283 ENV- and HERV-W ENV+ PASC subgroups; grey dots: PASC HERV-W ENV- subgroup; orange dots: PASC HERV-W  
284 ENV+ subgroup. E, IgG anti-SARS-CoV-2 Nucleocapsid; F, IgG anti-SARS-CoV-2 Spike. Comparison between PASC  
285 HERV-W ENV- and PASC HERV-W ENV+ subgroups for IgG anti-Nucleocapsid (G), and anti-Spike (H). The value on  
286 the Y-axis (U) represents the area under the curve (AUC) of the electrophoregram specific peak corresponding to the  
287 immunodetected Ig isotype from tested sera against each antigen.

288 **Figure 2. PASC serological IgM, IgA and IgE.** A, IgM anti-SARS-CoV-2 Nucleocapsid; B, IgM anti-SARS-CoV-2  
289 Spike IgM anti-S and N of two PASC patients with inconsistent results and diverging triplicate values were not be  
290 interpretable and therefore not taken into account in this analysis.; C, IgA anti-SARS-CoV-2 Nucleocapsid; D, IgA anti-  
291 SARS-CoV-2 Spike; E, IgE anti-SARS-CoV-2 Nucleocapsid and F, IgE anti-SARS-CoV-2 Spike. The value on Y axis  
292 (U) represents the area under the curve (AUC) of the electrophoregram specific peak corresponding to the  
293 immunodetected Ig isotype from tested sera against each antigen.

294 **Figure 3. Interleukine-6 (IL-6), neurofilament light chain (NFL) biomarkers and combination with HERV-W**  
295 **ENV or anti-nucleocapsid IgG (IgG anti-N) status stratifying PASC patients.** A, IL-6 dosages for controls (bleu  
296 dots), NNP (red dots) and PNP (dark red dots). B, IL-6 dosage comparisons between HERV-W ENV- and HERV-W  
297 ENV+ subgroups in PASC cohort. C, correlation between IL-6 and HERV-W ENV levels in serum. D, IL-6 levels in  
298 PASC patients stratified by: HERV-W ENV- / IgG anti-N- (grey dots), HERV-W ENV- / IgG anti-N+ (blue dots) and  
299 HERV-W ENV+ / IgG anti-N+ (red dots). E, NfL Z-Scores of controls (blue dots), NNP (red dots) and PNP (dark red  
300 dots). NfL Z-scores comparisons between HERV-W ENV- and HERV-W ENV+ subgroups in PASC cohort. G, NfL  
301 levels in different PASC subgroups: HERV-W ENV- / IgG anti-N- (grey dots), HERV-W ENV- / IgG anti-N+ (blue dots)  
302 and HERV-W ENV+ / IgG anti-N+ (red dots). H, Graphical presentation of patients' clusters defined by the selected  
303 serum biomarkers, within HERV-W ENV negative and HERV-W ENV positive subgroups. The sera positive for each  
304 biomarker are represented by dots in the colored circles; those negative for all parameters are in the grey oval.

305 **Figure 4. Comparison of clinical data between groups based on HERV-W ENV and serology profiles.** Three  
306 groups from the PASC cohort are represented based on main biomarkers results: HERV-W ENV+ /Igs anti-SARS-CoV-2  
307 Nucleocapsid (Ig anti-N) + ; HERV-W ENV- /Igs anti-SARS-CoV-2 Nucleocapsid (Ig anti-N) + and HERV-W ENV-  
308 /Igs anti-SARS-CoV-2 Nucleocapsid (Ig anti-N). Several parameters were studied: A, Processing speed; B, Attention; C,  
309 Executive function; D, Working Memory; E, Cognitive function; F, Fatigue; G, Anxiety; H, Depression and I, Recovery  
310 compared to the baseline.

311

312 **Conflict of Interest**

313 *HP, BC, JB and BC receive compensation from Geneuro-Innovation for their work. The other*  
314 *authors declare that the research was conducted in the absence of any commercial or financial*  
315 *relationships that could be construed as a potential conflict of interest.*

316

317 **Author Contributions**

318 IK : conceptualization of the study, evaluating all patients in the Neuro-COVID-19 clinic,  
319 supervising patients sample collection, manuscript editing and review

320 NW collaborators: Zack and Millenia: organized sample and data collection from all Neuro-PASC  
321 and control patients at Northwestern University, manuscript review

322 Barbara and Lavanya: Conceptualization of the study, assisted in sample and data collection from all  
323 Neuro-PASC and control patients at Northwestern University, editing and reviewing the manuscript

324 HP: conceptualization, supervision, formal analysis, investigation, data curation, writing and  
325 manuscript review.

326 AL, CB, SF: HERV-W-ENV detection, NfL, cytokines HERV-W-ENV detection, NfL, cytokines,  
327 serological analyses.

328 B.C.: methodology, management interpretation of analyses and manuscript review.

329 J.P: Serological and antigenemia analyses; graphs, figures drawing and manuscript review.

330 J.B.: PCR, serological and antigenemia analyses; graphs, figures drawing and manuscript review.

331 H.P. and E.O.: conceptualization, funding acquisition, supervision, formal analysis, investigation,  
332 data curation, writing original draft and manuscript review.

333 All authors contributed to the article and approved the submitted version.

334

335

## 336 **References**

337

338 1. Hamouda D, Jillella DV, Bhatt N, Koneru S, Frankel MR, Nogueira RG. Intraluminal carotid  
339 thrombosis and acute ischemic stroke associated with COVID-19. *J Neurol*. Dec 2021;268(12):4443-  
340 4447. doi:10.1007/s00415-021-10562-1

341 2. Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy-  
342 associated morbidity in Covid-19 patients. *Ann Clin Transl Neurol*. Nov 2020;7(11):2221-2230.  
343 doi:10.1002/acn3.51210

344 3. Nehme M, Braillard O, Chappuis F, CoviCare Study T, Guessous I. The chronification of  
345 post-COVID condition associated with neurocognitive symptoms, functional impairment and  
346 increased healthcare utilization. *Sci Rep*. Aug 25 2022;12(1):14505. doi:10.1038/s41598-022-18673-  
347 z

348 4. CDC. *Prevalence of long COVID in the USA*. 2022.

349 5. WHO. *Long COVID in the WHO European Region*. 2022.

350 6. Global Burden of Disease Long CC, Wulf Hanson S, Abbafati C, et al. Estimated Global  
351 Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters  
352 Following Symptomatic COVID-19 in 2020 and 2021. *JAMA*. Oct 25 2022;328(16):1604-1615.  
353 doi:10.1001/jama.2022.18931

354 7. Ali ST, Kang AK, Patel TR, et al. Evolution of neurologic symptoms in non-hospitalized  
355 COVID-19 "long haulers". *Ann Clin Transl Neurol*. Jul 2022;9(7):950-961. doi:10.1002/acn3.51570

356 8. Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive  
357 dysfunction in non-hospitalized Covid-19 "long haulers". *Ann Clin Transl Neurol*. May  
358 2021;8(5):1073-1085. doi:10.1002/acn3.51350

359 9. O'Hare AM, Vig EK, Iwashyna TJ, et al. Complexity and Challenges of the Clinical  
360 Diagnosis and Management of Long COVID. *JAMA Netw Open*. Nov 1 2022;5(11):e2240332.  
361 doi:10.1001/jamanetworkopen.2022.40332

362 10. Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN. The envelope protein  
363 of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and  
364 promotes Th1-like responses. *J Immunol*. Jun 15 2006;176(12):7636-44.

365 11. Firouzi R, Rolland A, Michel M, et al. Multiple sclerosis-associated retrovirus particles cause  
366 T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. *J*  
367 *Neurovirol*. Feb 2003;9(1):79-93. doi:10.1080/13550280390173328

368 MN2N2T34QVXHRWNY [pii]

369 12. Kremer D, Gruchot J, Weyers V, et al. pHERV-W envelope protein fuels microglial cell-  
370 dependent damage of myelinated axons in multiple sclerosis. *Proc Natl Acad Sci U S A*. Jul 23  
371 2019;116(30):15216-15225. doi:10.1073/pnas.1901283116


372 13. Ruprecht K, Obojes K, Wengel V, et al. Regulation of human endogenous retrovirus W  
373 protein expression by herpes simplex virus type 1: implications for multiple sclerosis. *J Neurovirol*.  
374 Feb 2006;12(1):65-71. doi:T6G5G8M106986441 [pii]

375 10.1080/13550280600614973

- 376 14. Charvet B, Reynaud JM, Gourru-Lesimple G, Perron H, Marche PN, Horvat B. Induction of  
377 Proinflammatory Multiple Sclerosis-Associated Retrovirus Envelope Protein by Human Herpesvirus-  
378 6A and CD46 Receptor Engagement. *Front Immunol.* 2018;9:2803. doi:10.3389/fimmu.2018.02803
- 379 15. Li F, Nellaker C, Sabunciyan S, et al. Transcriptional derepression of the ERVWE1 locus  
380 following influenza A virus infection. *J Virol.* Apr 2014;88(8):4328-37. doi:10.1128/JVI.03628-13
- 381 16. Balestrieri E, Minutolo A, Petrone V, et al. Evidence of the pathogenic HERV-W envelope  
382 expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients.  
383 *EBioMedicine.* Apr 2021;66:103341. doi:10.1016/j.ebiom.2021.103341
- 384 17. Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV-  
385 2. *Nat Immunol.* Feb 2022;23(2):165-176. doi:10.1038/s41590-021-01091-0
- 386 18. Fisse AL, Pitarokoili K, Leppert D, et al. Serum neurofilament light chain as outcome marker  
387 for intensive care unit patients. *J Neurol.* Apr 2021;268(4):1323-1329. doi:10.1007/s00415-020-  
388 10277-9
- 389 19. Lai JS, Wagner LI, Jacobsen PB, Cella D. Self-reported cognitive concerns and abilities: two  
390 sides of one coin? *Psychooncology.* Oct 2014;23(10):1133-41. doi:10.1002/pon.3522
- 391 20. Lai JS, Cella D, Choi S, et al. How item banks and their application can influence  
392 measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. *Arch Phys*  
393 *Med Rehabil.* Oct 2011;92(10 Suppl):S20-7. doi:10.1016/j.apmr.2010.08.033
- 394 21. Wilson KD, Ameen M, Guo H, et al. Endogenous Retrovirus-Derived lncRNA BANCR  
395 Promotes Cardiomyocyte Migration in Humans and Non-human Primates. *Dev Cell.* Sep 28  
396 2020;54(6):694-709 e9. doi:10.1016/j.devcel.2020.07.006
- 397 22. Chishima T, Iwakiri J, Hamada M. Identification of Transposable Elements Contributing to  
398 Tissue-Specific Expression of Long Non-Coding RNAs. *Genes (Basel).* Jan 9  
399 2018;9(1)doi:10.3390/genes9010023
- 400 23. Johansson EM, Bouchet D, Tamouza R, et al. Human endogenous retroviral protein triggers  
401 deficit in glutamate synapse maturation and behaviors associated with psychosis. *Science Advances.*  
402 2020;6(29):eabc0708. doi:10.1126/sciadv.abc0708
- 403 24. Madeira A, Burgelin I, Perron H, Curtin F, Lang AB, Faucard R. MSR-V envelope protein is a  
404 potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in  
405 multiple sclerosis treatment. *J Neuroimmunol.* Feb 15 2016;291:29-38.  
406 doi:10.1016/j.jneuroim.2015.12.006
- 407 25. Duperray A, Barbe D, Raguenez G, et al. Inflammatory response of endothelial cells to a  
408 human endogenous retrovirus associated with multiple sclerosis is mediated by TLR4. *Int Immunol.*  
409 Nov 2015;27(11):545-53. doi:10.1093/intimm/dxv025
- 410 26. Kremer D, Schichel T, Forster M, et al. Human endogenous retrovirus type W envelope  
411 protein inhibits oligodendroglial precursor cell differentiation. *Ann Neurol.* Nov 2013;74(5):721-32.  
412 doi:10.1002/ana.23970
- 413 27. Chitnis T, Gonzalez C, Healy BC, et al. Neurofilament light chain serum levels correlate with  
414 10-year MRI outcomes in multiple sclerosis. *Ann Clin Transl Neurol.* Dec 2018;5(12):1478-1491.  
415 doi:10.1002/acn3.638
- 416 28. Harp C, Thanei GA, Jia X, et al. Development of an age-adjusted model for blood  
417 neurofilament light chain. *Ann Clin Transl Neurol.* Apr 2022;9(4):444-453. doi:10.1002/acn3.51524

- 418 29. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat*  
419 *Med.* Jul 2020;26(7):1017-1032. doi:10.1038/s41591-020-0968-3
- 420 30. Vartanian K, Fish D, Gronowski B, Kenton N, Robicsek A. Patient-Reported Outcomes for  
421 Fully Vaccinated COVID-19 Patients Over 6 Weeks: The Experiences of Clinical Breakthrough  
422 Cases. *Patient.* Nov 7 2022:1-12. doi:10.1007/s40271-022-00605-8
- 423

Figure 1



IgM anti-SARS-CoV-2 Nucleocapsid      IgA anti-SARS-CoV-2 Spike





Figure 3



**Figure 4**

medRxiv preprint doi: <https://doi.org/10.1101/2023.03.31.23288003>; this version posted April 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

